On December 22, 2021 AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, reported that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th (Press release, AVEO, DEC 22, 2021, View Source [SID1234597594]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fireside chat with AVEO’s management team and H.C. Wainwright research analyst Swayampakula Ramakanth will be available on-demand as of 7 a.m. EST on Monday, January 10th, by visiting the Calendar of Events sub-section within the Investors section of the Company’s website at www.aveooncology.com.